Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

INTRODUCTION: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we investigate resistance mechanisms to each drug alone, or to their combination u...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wang, Yen-Chao, Morrison, Gladys, Gillihan, Ryan, Guo, Jun, Ward, Robin M, Fu, Xiaoyong, Botero, Maria F, Healy, Nuala A, Hilsenbeck, Susan G, Phillips, Gail Lewis, Chamness, Gary C, Rimawi, Mothaffar F, Osborne, C Kent, Schiff, Rachel
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2011
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326563/
https://ncbi.nlm.nih.gov/pubmed/22123186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3067
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi